# Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers

> **NCT02392468** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 61 (actual)

## Conditions studied

- Schizophrenia
- Alzheimer Disease

## Interventions

- **DRUG:** Placebo matching BI 409306 25 mg
- **DRUG:** Placebo matching BI 409306 50 mg
- **DRUG:** BI 409306 25 mg
- **DRUG:** BI 409306 50 mg

## Key facts

- **NCT ID:** NCT02392468
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-15
- **Primary completion:** 2017-08-03
- **Final completion:** 2017-08-10
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2024-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02392468

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02392468, "Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02392468. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*